 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
Formerly MEN2a/2b edit
MEN2a and 2b are the CURRENT names, MEN 3 is outdated following the discovery that MEN2B was caused by a mutation to the same gene (met->thr mutation on RET). I've changed the article accordingly. —Preceding unsigned comment added by ChillyMD (talk • contribs) 13:53, 23 January 2009 (UTC)
As a drug target edit
Cabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC says cabozantinib is also an inhibitor of RET and ROS1. May explain good results in NSCLC. - Rod57 (talk) 11:59, 3 December 2016 (UTC)